Patient ID

Some RA patients don’t fit the standard profile

Identifying an autoinflammatory component in your patient’s RA is a multifactorial process. Start by reviewing a few general criteria for some important context.

Download this chart
Three large circles surround a small circle that says “RA WITH AUTOINFLAMMATORY COMPONENTS.” The larger circles have descriptions of different symptoms, treatment failures, and elevated acute-phase reactants
Three large circles surround a small circle that says “RA WITH AUTOINFLAMMATORY COMPONENTS.” The larger circles have descriptions of different symptoms, treatment failures, and elevated acute-phase reactants
Next

Answer a few questions to see whether KINERET could be right for your patient.

Answer a few questions to see whether KINERET could be right for your patient.

Next
Download this chart

Find out if your patient is right for KINERET.

Just answer these 4 simple questions.

If you have a patient with difficult-to-treat RA, this 60-second survey may help you determine whether he or she is suitable for KINERET.

Begin

PP-5625

  • 1
    Steroid Response
  • 2
    Treatment History
  • 3
    Signs and Symptoms of Inflammation
  • 4
    Acute Phase Reactants
  • Results
An illustrated syringe
Has your patient been prescribed steroids?
Does your patient have persisting inflammatory symptoms despite steroid treatment?
Continue
Has your patient tried and failed any treatments within the following therapy classes? Check all that apply.
An illustrated shield with an X on it
Continue
How many signs and symptoms of extraarticular inflammation has your patient experienced? Check all that apply.
Continue
An illustrated arrow pointing in an upward trend
Has your patient exhibited any other potential indicators, such as elevated CRP or ESR levels?
Continue

Kineret candidates typically try and fail steroids, DMARDs, and anti-TNFs before initiating therapy, although this isn’t always the case.1, 3, 5

An illustrated silhouette of a doctor
Learn About the IL-1-Driven RA Patient Experience

While Kineret may not be right for your patient at this time, it is important to understand the signs and symptoms of interleukin-1 (IL-1)—driven inflammation for future consideration1-5:

An illustrated silhouette of a doctor
  • Steroid resistance
  • Lack of response to DMARDs and anti-TNFs
  • Extra-articular signs and symptoms, such as fever, rash, headache, fatigue, muscle-related symptoms, keratoconjunctivitis sicca or dry eyes
  • Elevated acute phase reactants (CRP and ESR)
Learn About the IL-1-Driven RA Patient Experience

Your patient might be right for Kineret

Based on your answers, your patient’s RA might be mediated by interleukin-1 (IL-1), which could mean he or she is a candidate for Kineret.3

Steroid resistance, lack of response to DMARDs/anti-TNFs, extra-articular evidence of inflammation, or elevated CRP or ESR can be signs of IL-1–driven autoinflammation.1-5

To refer your patient for Kineret treatment, download our referral form.

Download the referral form
PREVIOUS:   Difficult-to-Treat RA
NEXT:   RA Efficacy
Indications and Important Safety Information
INDICATIONS
KINERET® (anakinra) is an interleukin-1 receptor antagonist indicated for:
Rheumatoid Arthritis (RA)
  • Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs)
Cryopyrin-Associated Periodic Syndromes (CAPS)
  • Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
  • Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
IMPORTANT SAFETY INFORMATION
  • KINERET is contraindicated in patients with known hypersensitivity to E. coli–derived proteins, KINERET, or to any components of the product
  • In RA, discontinue use if serious infection develops. In KINERET-treated NOMID or DIRA patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections
  • Use in combination with Tumor Necrosis Factor (TNF)-blocking agents is not recommended
  • Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. Patients with DIRA may have an increased risk of allergic reactions, particularly in the first several weeks after starting KINERET treatment
  • The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known
  • Live vaccines should not be given concurrently with KINERET
  • Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year

RA: Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain

NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis

DIRA: The most common AEs are upper respiratory tract infections, rash, pyrexia, influenza-like illness, and gastroenteritis

  • A higher rate of serious infections has been observed in RA patients treated with concurrent KINERET and etanercept therapy than in patients treated with etanercept alone. Use of KINERET in combination with TNF-blocking agents is not recommended
  • KINERET is indicated for use in pediatric patients with NOMID and DIRA
  • Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly
  • KINERET is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function
Please see full Prescribing Information.

References: 1. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720-3732. 2. Vela P. Extra-articular manifestations of rheumatoid arthritis, now. Eur Med J Rheumatol. 2014;1:103-112. 3. Savic S, Mistry A, Wilson AG, et al. Autoimmune-autoinflammatory rheumatoid arthritis overlaps: a rare but potentially important subgroup of diseases. RMD Open. 2017;3(2):e000550. 4. KINERET [Prescribing Information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ). 5. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26. 6. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.